Those in the project will be collaborating in the research of cannabinoid and terpenoid profiles of 25 of WeedMD’s cannabis strains.
This data will then be added to an international database that correlates the pharmacological effects of the different strains.
From there, the most effective cannabis treatments - strains, dose and route of administration - for clinical purposes can be determined.
This is the first of several research and development initiatives WeedMD is working on as the firm develops its medical cannabis for both the domestic and global markets.
“We are proud to be at the forefront of investing in cannabis research, awareness and education,” said chief scientific officer Luc Duchesne.
“There are hundreds of cannabis strains available to medical patients, but each of these strains has a unique chemical profile, as well potentially unique medical properties.
“A significant barrier to the standardization of medical cannabis is identifying strains that are effective in the treatment of specific medical conditions and Technion is making ground-breaking discoveries to this effect.”
WeedMD shares rose 3.7% to C$2.26 on Wednesday morning.